nodes	percent_of_prediction	percent_of_DWPC	metapath
Varenicline—CHRFAM7A—ovarian follicle—hematologic cancer	0.0577	0.307	CbGeAlD
Varenicline—CHRNA7—ovarian follicle—hematologic cancer	0.0466	0.248	CbGeAlD
Varenicline—CHRNA3—hematopoietic system—hematologic cancer	0.00862	0.0459	CbGeAlD
Varenicline—CHRFAM7A—hematopoietic system—hematologic cancer	0.00697	0.0371	CbGeAlD
Varenicline—CHRNB2—blood—hematologic cancer	0.00589	0.0313	CbGeAlD
Varenicline—CHRNB2—bone marrow—hematologic cancer	0.0057	0.0303	CbGeAlD
Varenicline—CHRNA7—hematopoietic system—hematologic cancer	0.00563	0.03	CbGeAlD
Varenicline—CHRNA4—hematopoietic system—hematologic cancer	0.00555	0.0296	CbGeAlD
Varenicline—CHRNB2—lung—hematologic cancer	0.00516	0.0275	CbGeAlD
Varenicline—CHRNA3—lung—hematologic cancer	0.00501	0.0266	CbGeAlD
Varenicline—CHRNB2—testis—hematologic cancer	0.00487	0.0259	CbGeAlD
Varenicline—CHRNA3—testis—hematologic cancer	0.00472	0.0251	CbGeAlD
Varenicline—CHRFAM7A—blood—hematologic cancer	0.00462	0.0246	CbGeAlD
Varenicline—CHRFAM7A—testis—hematologic cancer	0.00382	0.0203	CbGeAlD
Varenicline—CHRNA7—blood—hematologic cancer	0.00373	0.0198	CbGeAlD
Varenicline—CHRNB2—lymph node—hematologic cancer	0.00353	0.0188	CbGeAlD
Varenicline—CHRNA3—lymph node—hematologic cancer	0.00342	0.0182	CbGeAlD
Varenicline—CHRNA4—lung—hematologic cancer	0.00323	0.0172	CbGeAlD
Varenicline—CHRNA7—testis—hematologic cancer	0.00309	0.0164	CbGeAlD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—TLX3—hematologic cancer	0.00206	0.0304	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—PBX1—hematologic cancer	0.00143	0.0211	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—TLX3—hematologic cancer	0.00141	0.0208	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—PER3—hematologic cancer	0.00128	0.0188	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—TLX3—hematologic cancer	0.00115	0.017	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—TCF3—hematologic cancer	0.00113	0.0167	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—PER2—hematologic cancer	0.00108	0.016	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—CRY2—hematologic cancer	0.00108	0.016	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—CRY1—hematologic cancer	0.00108	0.016	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—GATA2—hematologic cancer	0.00104	0.0154	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—PBX1—hematologic cancer	0.000976	0.0144	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—ID3—hematologic cancer	0.000922	0.0136	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—RET—hematologic cancer	0.000921	0.0136	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—PER1—hematologic cancer	0.000822	0.0121	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—KMT2A—hematologic cancer	0.000822	0.0121	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—PBX1—hematologic cancer	0.000796	0.0118	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—TCF3—hematologic cancer	0.000772	0.0114	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—TOP1—hematologic cancer	0.000752	0.0111	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—ID2—hematologic cancer	0.000733	0.0108	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—GATA2—hematologic cancer	0.000712	0.0105	CbGpPWpGaD
Varenicline—CHRNA6—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ADCY7—hematologic cancer	0.000673	0.00994	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—RUNX3—hematologic cancer	0.000649	0.00958	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—TCF3—hematologic cancer	0.000629	0.00929	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—RET—hematologic cancer	0.000629	0.00929	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—HDAC9—hematologic cancer	0.000628	0.00928	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—FOXM1—hematologic cancer	0.000622	0.00918	CbGpPWpGaD
Varenicline—CHRNA6—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CAMK2D—hematologic cancer	0.000599	0.00884	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—MYB—hematologic cancer	0.000599	0.00884	CbGpPWpGaD
Varenicline—CHRNB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ADCY7—hematologic cancer	0.000593	0.00875	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—ARNTL—hematologic cancer	0.000586	0.00865	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—GATA2—hematologic cancer	0.000581	0.00857	CbGpPWpGaD
Varenicline—CHRNA6—Transmission across Chemical Synapses—SLC22A1—hematologic cancer	0.000552	0.00816	CbGpPWpGaD
Varenicline—CHRNB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CAMK2D—hematologic cancer	0.000527	0.00779	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—RET—hematologic cancer	0.000513	0.00757	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—IL13—hematologic cancer	0.000512	0.00756	CbGpPWpGaD
Varenicline—CHRNA6—Transmission across Chemical Synapses—ADCY7—hematologic cancer	0.000506	0.00747	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—JUND—hematologic cancer	0.000498	0.00735	CbGpPWpGaD
Varenicline—CHRNB2—Transmission across Chemical Synapses—SLC22A1—hematologic cancer	0.000486	0.00718	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—GATA3—hematologic cancer	0.000462	0.00682	CbGpPWpGaD
Varenicline—CHRNA6—Transmission across Chemical Synapses—CAMK2D—hematologic cancer	0.00045	0.00665	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—CST3—hematologic cancer	0.000447	0.0066	CbGpPWpGaD
Varenicline—CHRNB2—Transmission across Chemical Synapses—ADCY7—hematologic cancer	0.000446	0.00658	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—RUNX3—hematologic cancer	0.000443	0.00654	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—HDAC9—hematologic cancer	0.000429	0.00634	CbGpPWpGaD
Varenicline—CHRNA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ADCY7—hematologic cancer	0.000427	0.0063	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—FOXM1—hematologic cancer	0.000425	0.00627	CbGpPWpGaD
Varenicline—CHRNA6—Neuronal System—SLC22A1—hematologic cancer	0.000423	0.00625	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—PML—hematologic cancer	0.000421	0.00621	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—MYB—hematologic cancer	0.000409	0.00604	CbGpPWpGaD
Varenicline—CHRNA7—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ADCY7—hematologic cancer	0.000405	0.00598	CbGpPWpGaD
Varenicline—CHRNB2—Transmission across Chemical Synapses—CAMK2D—hematologic cancer	0.000396	0.00585	CbGpPWpGaD
Varenicline—CHRNA6—Neuronal System—ADCY7—hematologic cancer	0.000388	0.00573	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—TOP2A—hematologic cancer	0.000385	0.00568	CbGpPWpGaD
Varenicline—CHRNA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CAMK2D—hematologic cancer	0.00038	0.00561	CbGpPWpGaD
Varenicline—CHRNA6—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—PRKCG—hematologic cancer	0.000379	0.00559	CbGpPWpGaD
Varenicline—CHRNB2—Neuronal System—SLC22A1—hematologic cancer	0.000373	0.0055	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—AR—hematologic cancer	0.000367	0.00541	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—EZH2—hematologic cancer	0.000366	0.0054	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—RUNX3—hematologic cancer	0.000361	0.00534	CbGpPWpGaD
Varenicline—CHRNA7—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CAMK2D—hematologic cancer	0.00036	0.00532	CbGpPWpGaD
Varenicline—CHRNA3—Transmission across Chemical Synapses—SLC22A1—hematologic cancer	0.00035	0.00517	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—HDAC9—hematologic cancer	0.00035	0.00517	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—IL13—hematologic cancer	0.00035	0.00517	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—FOXM1—hematologic cancer	0.000346	0.00512	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—HDAC2—hematologic cancer	0.000345	0.0051	CbGpPWpGaD
Varenicline—CHRNA6—Neuronal System—CAMK2D—hematologic cancer	0.000345	0.00509	CbGpPWpGaD
Varenicline—CHRNB2—Neuronal System—ADCY7—hematologic cancer	0.000341	0.00504	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—MYB—hematologic cancer	0.000333	0.00492	CbGpPWpGaD
Varenicline—CHRNB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—PRKCG—hematologic cancer	0.000333	0.00492	CbGpPWpGaD
Varenicline—CHRNA7—Transmission across Chemical Synapses—SLC22A1—hematologic cancer	0.000332	0.00491	CbGpPWpGaD
Varenicline—CHRNA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ADCY7—hematologic cancer	0.00033	0.00488	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—HES1—hematologic cancer	0.000322	0.00476	CbGpPWpGaD
Varenicline—CHRNA3—Transmission across Chemical Synapses—ADCY7—hematologic cancer	0.000321	0.00474	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—IL10—hematologic cancer	0.00032	0.00473	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—GATA3—hematologic cancer	0.000316	0.00466	CbGpPWpGaD
Varenicline—CHRNA7—Transmission across Chemical Synapses—ADCY7—hematologic cancer	0.000305	0.0045	CbGpPWpGaD
Varenicline—CHRNB2—Neuronal System—CAMK2D—hematologic cancer	0.000304	0.00449	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—NR3C1—hematologic cancer	0.000296	0.00438	CbGpPWpGaD
Varenicline—CHRNA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CAMK2D—hematologic cancer	0.000294	0.00434	CbGpPWpGaD
Varenicline—CHRNA3—Transmission across Chemical Synapses—CAMK2D—hematologic cancer	0.000285	0.00422	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—IL13—hematologic cancer	0.000285	0.00421	CbGpPWpGaD
Varenicline—CHRNA6—Transmission across Chemical Synapses—PRKCG—hematologic cancer	0.000285	0.0042	CbGpPWpGaD
Varenicline—CHRNA6—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CREB1—hematologic cancer	0.00028	0.00414	CbGpPWpGaD
Varenicline—CHRNA6—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—hematologic cancer	0.000277	0.00409	CbGpPWpGaD
Varenicline—CHRNA4—Transmission across Chemical Synapses—SLC22A1—hematologic cancer	0.000271	0.004	CbGpPWpGaD
Varenicline—CHRNA7—Transmission across Chemical Synapses—CAMK2D—hematologic cancer	0.000271	0.004	CbGpPWpGaD
Varenicline—CHRNA3—Neuronal System—SLC22A1—hematologic cancer	0.000268	0.00396	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—NCOR1—hematologic cancer	0.000262	0.00386	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—GATA3—hematologic cancer	0.000257	0.0038	CbGpPWpGaD
Varenicline—CHRNA7—Neuronal System—SLC22A1—hematologic cancer	0.000255	0.00376	CbGpPWpGaD
Varenicline—CHRNB2—Transmission across Chemical Synapses—PRKCG—hematologic cancer	0.000251	0.0037	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—AR—hematologic cancer	0.00025	0.0037	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—PRKCG—hematologic cancer	0.00025	0.00369	CbGpPWpGaD
Varenicline—CHRNA4—Transmission across Chemical Synapses—ADCY7—hematologic cancer	0.000248	0.00367	CbGpPWpGaD
Varenicline—CHRNB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CREB1—hematologic cancer	0.000247	0.00365	CbGpPWpGaD
Varenicline—CHRNA3—Neuronal System—ADCY7—hematologic cancer	0.000246	0.00363	CbGpPWpGaD
Varenicline—CHRNB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—hematologic cancer	0.000244	0.0036	CbGpPWpGaD
Varenicline—CHRNA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—PRKCG—hematologic cancer	0.00024	0.00354	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—FAS—hematologic cancer	0.000235	0.00346	CbGpPWpGaD
Varenicline—CHRNA7—Neuronal System—ADCY7—hematologic cancer	0.000233	0.00344	CbGpPWpGaD
Varenicline—CHRNA6—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—hematologic cancer	0.000232	0.00343	CbGpPWpGaD
Varenicline—CHRNA7—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—PRKCG—hematologic cancer	0.000228	0.00336	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—CREB1—hematologic cancer	0.000226	0.00334	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—IL6R—hematologic cancer	0.000221	0.00326	CbGpPWpGaD
Varenicline—CHRNA4—Transmission across Chemical Synapses—CAMK2D—hematologic cancer	0.000221	0.00326	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—CREBBP—hematologic cancer	0.000221	0.00326	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—HES1—hematologic cancer	0.00022	0.00325	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—IL10—hematologic cancer	0.000219	0.00323	CbGpPWpGaD
Varenicline—CHRNA3—Neuronal System—CAMK2D—hematologic cancer	0.000219	0.00323	CbGpPWpGaD
Varenicline—CHRNA6—Neuronal System—PRKCG—hematologic cancer	0.000218	0.00322	CbGpPWpGaD
Varenicline—CHRNA6—Transmission across Chemical Synapses—CREB1—hematologic cancer	0.000211	0.00311	CbGpPWpGaD
Varenicline—CHRNA6—Transmission across Chemical Synapses—BRAF—hematologic cancer	0.000208	0.00307	CbGpPWpGaD
Varenicline—CHRNA4—Neuronal System—SLC22A1—hematologic cancer	0.000208	0.00306	CbGpPWpGaD
Varenicline—CHRNA7—Neuronal System—CAMK2D—hematologic cancer	0.000208	0.00306	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—CDK4—hematologic cancer	0.000206	0.00305	CbGpPWpGaD
Varenicline—CHRNB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—hematologic cancer	0.000204	0.00302	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—AR—hematologic cancer	0.000204	0.00301	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—NR3C1—hematologic cancer	0.000203	0.00299	CbGpPWpGaD
Varenicline—CHRNB2—Neuronal System—PRKCG—hematologic cancer	0.000192	0.00284	CbGpPWpGaD
Varenicline—CHRNA4—Neuronal System—ADCY7—hematologic cancer	0.00019	0.00281	CbGpPWpGaD
Varenicline—CHRNA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—PRKCG—hematologic cancer	0.000186	0.00274	CbGpPWpGaD
Varenicline—CHRNB2—Transmission across Chemical Synapses—CREB1—hematologic cancer	0.000186	0.00274	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—CREB1—hematologic cancer	0.000185	0.00273	CbGpPWpGaD
Varenicline—CHRNB2—Transmission across Chemical Synapses—BRAF—hematologic cancer	0.000183	0.00271	CbGpPWpGaD
Varenicline—CHRNA3—Transmission across Chemical Synapses—PRKCG—hematologic cancer	0.00018	0.00266	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—HES1—hematologic cancer	0.000179	0.00265	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—IL10—hematologic cancer	0.000178	0.00264	CbGpPWpGaD
Varenicline—CHRNA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CREB1—hematologic cancer	0.000178	0.00263	CbGpPWpGaD
Varenicline—CHRNA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—hematologic cancer	0.000176	0.00259	CbGpPWpGaD
Varenicline—CHRNA6—Transmission across Chemical Synapses—MDM2—hematologic cancer	0.000174	0.00258	CbGpPWpGaD
Varenicline—CHRNA7—Transmission across Chemical Synapses—PRKCG—hematologic cancer	0.000171	0.00253	CbGpPWpGaD
Varenicline—CHRNA4—Neuronal System—CAMK2D—hematologic cancer	0.000169	0.0025	CbGpPWpGaD
Varenicline—CHRNA7—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CREB1—hematologic cancer	0.000169	0.00249	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—IL1B—hematologic cancer	0.000168	0.00248	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—CASP3—hematologic cancer	0.000168	0.00248	CbGpPWpGaD
Varenicline—CHRNA7—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—hematologic cancer	0.000167	0.00246	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—NR3C1—hematologic cancer	0.000165	0.00244	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—JUN—hematologic cancer	0.000163	0.0024	CbGpPWpGaD
Varenicline—CHRNA6—Neuronal System—CREB1—hematologic cancer	0.000162	0.00239	CbGpPWpGaD
Varenicline—CHRNA6—Neuronal System—BRAF—hematologic cancer	0.00016	0.00236	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—CREB1—hematologic cancer	0.000155	0.00228	CbGpPWpGaD
Varenicline—CHRNB2—Transmission across Chemical Synapses—MDM2—hematologic cancer	0.000154	0.00227	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—IL6R—hematologic cancer	0.000151	0.00223	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—CREBBP—hematologic cancer	0.000151	0.00223	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—EP300—hematologic cancer	0.00015	0.00222	CbGpPWpGaD
Varenicline—CHRNA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—hematologic cancer	0.000147	0.00217	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—VEGFA—hematologic cancer	0.000142	0.0021	CbGpPWpGaD
Varenicline—CHRNB2—Neuronal System—CREB1—hematologic cancer	0.000142	0.0021	CbGpPWpGaD
Varenicline—CHRNB2—Neuronal System—BRAF—hematologic cancer	0.00014	0.00207	CbGpPWpGaD
Varenicline—CHRNA4—Transmission across Chemical Synapses—PRKCG—hematologic cancer	0.00014	0.00206	CbGpPWpGaD
Varenicline—CHRNA7—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—hematologic cancer	0.00014	0.00206	CbGpPWpGaD
Varenicline—CHRNA3—Neuronal System—PRKCG—hematologic cancer	0.000138	0.00204	CbGpPWpGaD
Varenicline—CHRNA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CREB1—hematologic cancer	0.000138	0.00203	CbGpPWpGaD
Varenicline—CHRNA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—hematologic cancer	0.000136	0.00201	CbGpPWpGaD
Varenicline—CHRNA3—Transmission across Chemical Synapses—CREB1—hematologic cancer	0.000134	0.00197	CbGpPWpGaD
Varenicline—CHRNA6—Neuronal System—MDM2—hematologic cancer	0.000134	0.00197	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—JUN—hematologic cancer	0.000133	0.00196	CbGpPWpGaD
Varenicline—CHRNA3—Transmission across Chemical Synapses—BRAF—hematologic cancer	0.000132	0.00195	CbGpPWpGaD
Varenicline—CHRNA7—Neuronal System—PRKCG—hematologic cancer	0.000131	0.00194	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—PTEN—hematologic cancer	0.000129	0.0019	CbGpPWpGaD
Varenicline—CHRNA6—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—hematologic cancer	0.000127	0.00188	CbGpPWpGaD
Varenicline—CHRNA7—Transmission across Chemical Synapses—CREB1—hematologic cancer	0.000127	0.00187	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—CREB1—hematologic cancer	0.000126	0.00186	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—MAPK8—hematologic cancer	0.000126	0.00186	CbGpPWpGaD
Varenicline—CHRNA7—Transmission across Chemical Synapses—BRAF—hematologic cancer	0.000125	0.00185	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—IL6R—hematologic cancer	0.000123	0.00182	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—CREBBP—hematologic cancer	0.000123	0.00181	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—EP300—hematologic cancer	0.000123	0.00181	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—TNF—hematologic cancer	0.000122	0.0018	CbGpPWpGaD
Varenicline—CHRNB2—Neuronal System—MDM2—hematologic cancer	0.000118	0.00174	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—IL1B—hematologic cancer	0.000115	0.0017	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—CASP3—hematologic cancer	0.000115	0.00169	CbGpPWpGaD
Varenicline—CHRNA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—hematologic cancer	0.000114	0.00168	CbGpPWpGaD
Varenicline—CHRNB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—hematologic cancer	0.000112	0.00166	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—JUN—hematologic cancer	0.000111	0.00164	CbGpPWpGaD
Varenicline—CHRNA3—Transmission across Chemical Synapses—MDM2—hematologic cancer	0.000111	0.00163	CbGpPWpGaD
Varenicline—CHRNA4—Neuronal System—PRKCG—hematologic cancer	0.000107	0.00158	CbGpPWpGaD
Varenicline—CHRNA7—Transmission across Chemical Synapses—MDM2—hematologic cancer	0.000105	0.00155	CbGpPWpGaD
Varenicline—CHRNA4—Transmission across Chemical Synapses—CREB1—hematologic cancer	0.000103	0.00153	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—EP300—hematologic cancer	0.000103	0.00152	CbGpPWpGaD
Varenicline—CHRNA3—Neuronal System—CREB1—hematologic cancer	0.000102	0.00151	CbGpPWpGaD
Varenicline—CHRNA4—Transmission across Chemical Synapses—BRAF—hematologic cancer	0.000102	0.00151	CbGpPWpGaD
Varenicline—CHRNA3—Neuronal System—BRAF—hematologic cancer	0.000101	0.00149	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—IL6—hematologic cancer	9.84e-05	0.00145	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—VEGFA—hematologic cancer	9.72e-05	0.00144	CbGpPWpGaD
Varenicline—CHRNA7—Neuronal System—CREB1—hematologic cancer	9.72e-05	0.00143	CbGpPWpGaD
Varenicline—CHRNA7—Neuronal System—BRAF—hematologic cancer	9.6e-05	0.00142	CbGpPWpGaD
Varenicline—CHRNA6—Transmission across Chemical Synapses—HRAS—hematologic cancer	9.57e-05	0.00141	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—IL1B—hematologic cancer	9.36e-05	0.00138	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—CASP3—hematologic cancer	9.34e-05	0.00138	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—JUN—hematologic cancer	9.07e-05	0.00134	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—TP53—hematologic cancer	8.78e-05	0.0013	CbGpPWpGaD
Varenicline—CHRNA4—Transmission across Chemical Synapses—MDM2—hematologic cancer	8.56e-05	0.00126	CbGpPWpGaD
Varenicline—CHRNA3—Neuronal System—MDM2—hematologic cancer	8.47e-05	0.00125	CbGpPWpGaD
Varenicline—CHRNB2—Transmission across Chemical Synapses—HRAS—hematologic cancer	8.43e-05	0.00124	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—EP300—hematologic cancer	8.37e-05	0.00124	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—TNF—hematologic cancer	8.33e-05	0.00123	CbGpPWpGaD
Varenicline—CHRNA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—hematologic cancer	8.07e-05	0.00119	CbGpPWpGaD
Varenicline—CHRNA7—Neuronal System—MDM2—hematologic cancer	8.04e-05	0.00119	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—IL6—hematologic cancer	8.03e-05	0.00119	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—VEGFA—hematologic cancer	7.93e-05	0.00117	CbGpPWpGaD
Varenicline—CHRNA4—Neuronal System—CREB1—hematologic cancer	7.92e-05	0.00117	CbGpPWpGaD
Varenicline—CHRNA4—Neuronal System—BRAF—hematologic cancer	7.82e-05	0.00116	CbGpPWpGaD
Varenicline—CHRNA7—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—hematologic cancer	7.66e-05	0.00113	CbGpPWpGaD
Varenicline—CHRNA6—Neuronal System—HRAS—hematologic cancer	7.33e-05	0.00108	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—TNF—hematologic cancer	6.79e-05	0.001	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—IL6—hematologic cancer	6.72e-05	0.000993	CbGpPWpGaD
Varenicline—CHRNA4—Neuronal System—MDM2—hematologic cancer	6.56e-05	0.000968	CbGpPWpGaD
Varenicline—CHRNB2—Neuronal System—HRAS—hematologic cancer	6.46e-05	0.000953	CbGpPWpGaD
Varenicline—CHRNA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—hematologic cancer	6.24e-05	0.000922	CbGpPWpGaD
Varenicline—CHRNA3—Transmission across Chemical Synapses—HRAS—hematologic cancer	6.07e-05	0.000896	CbGpPWpGaD
Varenicline—CHRNA7—Transmission across Chemical Synapses—HRAS—hematologic cancer	5.76e-05	0.00085	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—IL6—hematologic cancer	5.48e-05	0.000809	CbGpPWpGaD
Varenicline—Vomiting—Cisplatin—hematologic cancer	5.16e-05	6.94e-05	CcSEcCtD
Varenicline—Hyperhidrosis—Prednisone—hematologic cancer	5.15e-05	6.93e-05	CcSEcCtD
Varenicline—Vision blurred—Methotrexate—hematologic cancer	5.15e-05	6.91e-05	CcSEcCtD
Varenicline—Mental disorder—Epirubicin—hematologic cancer	5.14e-05	6.91e-05	CcSEcCtD
Varenicline—Erythema multiforme—Doxorubicin—hematologic cancer	5.14e-05	6.9e-05	CcSEcCtD
Varenicline—Rash—Cisplatin—hematologic cancer	5.12e-05	6.88e-05	CcSEcCtD
Varenicline—Dermatitis—Cisplatin—hematologic cancer	5.12e-05	6.87e-05	CcSEcCtD
Varenicline—Erythema—Epirubicin—hematologic cancer	5.11e-05	6.86e-05	CcSEcCtD
Varenicline—Malnutrition—Epirubicin—hematologic cancer	5.11e-05	6.86e-05	CcSEcCtD
Varenicline—Diarrhoea—Etoposide—hematologic cancer	5.09e-05	6.84e-05	CcSEcCtD
Varenicline—Anorexia—Prednisone—hematologic cancer	5.08e-05	6.83e-05	CcSEcCtD
Varenicline—Eye disorder—Doxorubicin—hematologic cancer	5.08e-05	6.82e-05	CcSEcCtD
Varenicline—Ill-defined disorder—Methotrexate—hematologic cancer	5.07e-05	6.81e-05	CcSEcCtD
Varenicline—Tinnitus—Doxorubicin—hematologic cancer	5.06e-05	6.8e-05	CcSEcCtD
Varenicline—Anaemia—Methotrexate—hematologic cancer	5.05e-05	6.78e-05	CcSEcCtD
Varenicline—Feeling abnormal—Dexamethasone—hematologic cancer	5.05e-05	6.78e-05	CcSEcCtD
Varenicline—Feeling abnormal—Betamethasone—hematologic cancer	5.05e-05	6.78e-05	CcSEcCtD
Varenicline—Cardiac disorder—Doxorubicin—hematologic cancer	5.04e-05	6.77e-05	CcSEcCtD
Varenicline—Flatulence—Epirubicin—hematologic cancer	5.04e-05	6.76e-05	CcSEcCtD
Varenicline—Gastrointestinal pain—Betamethasone—hematologic cancer	5.01e-05	6.73e-05	CcSEcCtD
Varenicline—Gastrointestinal pain—Dexamethasone—hematologic cancer	5.01e-05	6.73e-05	CcSEcCtD
Varenicline—Dysgeusia—Epirubicin—hematologic cancer	5e-05	6.72e-05	CcSEcCtD
Varenicline—Hypersensitivity—Triamcinolone—hematologic cancer	4.97e-05	6.68e-05	CcSEcCtD
Varenicline—Back pain—Epirubicin—hematologic cancer	4.94e-05	6.64e-05	CcSEcCtD
Varenicline—Angiopathy—Doxorubicin—hematologic cancer	4.93e-05	6.62e-05	CcSEcCtD
Varenicline—Malaise—Methotrexate—hematologic cancer	4.92e-05	6.62e-05	CcSEcCtD
Varenicline—Dizziness—Etoposide—hematologic cancer	4.92e-05	6.61e-05	CcSEcCtD
Varenicline—Muscle spasms—Epirubicin—hematologic cancer	4.91e-05	6.6e-05	CcSEcCtD
Varenicline—Immune system disorder—Doxorubicin—hematologic cancer	4.91e-05	6.59e-05	CcSEcCtD
Varenicline—Vertigo—Methotrexate—hematologic cancer	4.91e-05	6.59e-05	CcSEcCtD
Varenicline—Mediastinal disorder—Doxorubicin—hematologic cancer	4.89e-05	6.58e-05	CcSEcCtD
Varenicline—Chills—Doxorubicin—hematologic cancer	4.87e-05	6.55e-05	CcSEcCtD
Varenicline—Urticaria—Dexamethasone—hematologic cancer	4.86e-05	6.53e-05	CcSEcCtD
Varenicline—Urticaria—Betamethasone—hematologic cancer	4.86e-05	6.53e-05	CcSEcCtD
Varenicline—Musculoskeletal discomfort—Prednisone—hematologic cancer	4.86e-05	6.53e-05	CcSEcCtD
Varenicline—Dizziness—Prednisolone—hematologic cancer	4.85e-05	6.52e-05	CcSEcCtD
Varenicline—Arrhythmia—Doxorubicin—hematologic cancer	4.85e-05	6.52e-05	CcSEcCtD
Varenicline—Asthenia—Triamcinolone—hematologic cancer	4.84e-05	6.5e-05	CcSEcCtD
Varenicline—Abdominal pain—Betamethasone—hematologic cancer	4.84e-05	6.5e-05	CcSEcCtD
Varenicline—Body temperature increased—Dexamethasone—hematologic cancer	4.84e-05	6.5e-05	CcSEcCtD
Varenicline—Body temperature increased—Betamethasone—hematologic cancer	4.84e-05	6.5e-05	CcSEcCtD
Varenicline—Abdominal pain—Dexamethasone—hematologic cancer	4.84e-05	6.5e-05	CcSEcCtD
Varenicline—Nausea—Cisplatin—hematologic cancer	4.82e-05	6.48e-05	CcSEcCtD
Varenicline—Insomnia—Prednisone—hematologic cancer	4.82e-05	6.48e-05	CcSEcCtD
Varenicline—Vision blurred—Epirubicin—hematologic cancer	4.82e-05	6.47e-05	CcSEcCtD
Varenicline—Pruritus—Triamcinolone—hematologic cancer	4.77e-05	6.41e-05	CcSEcCtD
Varenicline—Cough—Methotrexate—hematologic cancer	4.76e-05	6.4e-05	CcSEcCtD
Varenicline—Mental disorder—Doxorubicin—hematologic cancer	4.76e-05	6.39e-05	CcSEcCtD
Varenicline—Ill-defined disorder—Epirubicin—hematologic cancer	4.74e-05	6.37e-05	CcSEcCtD
Varenicline—Convulsion—Methotrexate—hematologic cancer	4.73e-05	6.36e-05	CcSEcCtD
Varenicline—Vomiting—Etoposide—hematologic cancer	4.73e-05	6.35e-05	CcSEcCtD
Varenicline—Malnutrition—Doxorubicin—hematologic cancer	4.73e-05	6.35e-05	CcSEcCtD
Varenicline—Erythema—Doxorubicin—hematologic cancer	4.73e-05	6.35e-05	CcSEcCtD
Varenicline—Anaemia—Epirubicin—hematologic cancer	4.72e-05	6.34e-05	CcSEcCtD
Varenicline—Agitation—Epirubicin—hematologic cancer	4.7e-05	6.31e-05	CcSEcCtD
Varenicline—CHRNA4—Transmission across Chemical Synapses—HRAS—hematologic cancer	4.69e-05	0.000693	CbGpPWpGaD
Varenicline—Dyspepsia—Prednisone—hematologic cancer	4.69e-05	6.31e-05	CcSEcCtD
Varenicline—Rash—Etoposide—hematologic cancer	4.69e-05	6.3e-05	CcSEcCtD
Varenicline—Dermatitis—Etoposide—hematologic cancer	4.69e-05	6.3e-05	CcSEcCtD
Varenicline—Headache—Etoposide—hematologic cancer	4.66e-05	6.26e-05	CcSEcCtD
Varenicline—Flatulence—Doxorubicin—hematologic cancer	4.66e-05	6.26e-05	CcSEcCtD
Varenicline—CHRNA3—Neuronal System—HRAS—hematologic cancer	4.65e-05	0.000687	CbGpPWpGaD
Varenicline—Arthralgia—Methotrexate—hematologic cancer	4.65e-05	6.25e-05	CcSEcCtD
Varenicline—Myalgia—Methotrexate—hematologic cancer	4.65e-05	6.25e-05	CcSEcCtD
Varenicline—Chest pain—Methotrexate—hematologic cancer	4.65e-05	6.25e-05	CcSEcCtD
Varenicline—Decreased appetite—Prednisone—hematologic cancer	4.64e-05	6.23e-05	CcSEcCtD
Varenicline—Dysgeusia—Doxorubicin—hematologic cancer	4.63e-05	6.22e-05	CcSEcCtD
Varenicline—Rash—Prednisolone—hematologic cancer	4.63e-05	6.22e-05	CcSEcCtD
Varenicline—Dermatitis—Prednisolone—hematologic cancer	4.62e-05	6.21e-05	CcSEcCtD
Varenicline—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	4.62e-05	6.2e-05	CcSEcCtD
Varenicline—Malaise—Epirubicin—hematologic cancer	4.61e-05	6.19e-05	CcSEcCtD
Varenicline—Fatigue—Prednisone—hematologic cancer	4.6e-05	6.18e-05	CcSEcCtD
Varenicline—Headache—Prednisolone—hematologic cancer	4.6e-05	6.18e-05	CcSEcCtD
Varenicline—Discomfort—Methotrexate—hematologic cancer	4.59e-05	6.17e-05	CcSEcCtD
Varenicline—Vertigo—Epirubicin—hematologic cancer	4.59e-05	6.17e-05	CcSEcCtD
Varenicline—Syncope—Epirubicin—hematologic cancer	4.58e-05	6.16e-05	CcSEcCtD
Varenicline—Back pain—Doxorubicin—hematologic cancer	4.57e-05	6.14e-05	CcSEcCtD
Varenicline—Constipation—Prednisone—hematologic cancer	4.56e-05	6.13e-05	CcSEcCtD
Varenicline—Muscle spasms—Doxorubicin—hematologic cancer	4.55e-05	6.11e-05	CcSEcCtD
Varenicline—Palpitations—Epirubicin—hematologic cancer	4.52e-05	6.07e-05	CcSEcCtD
Varenicline—Loss of consciousness—Epirubicin—hematologic cancer	4.49e-05	6.03e-05	CcSEcCtD
Varenicline—Dizziness—Triamcinolone—hematologic cancer	4.46e-05	5.99e-05	CcSEcCtD
Varenicline—Cough—Epirubicin—hematologic cancer	4.46e-05	5.99e-05	CcSEcCtD
Varenicline—Vision blurred—Doxorubicin—hematologic cancer	4.46e-05	5.99e-05	CcSEcCtD
Varenicline—Convulsion—Epirubicin—hematologic cancer	4.43e-05	5.95e-05	CcSEcCtD
Varenicline—Infection—Methotrexate—hematologic cancer	4.43e-05	5.95e-05	CcSEcCtD
Varenicline—Nausea—Etoposide—hematologic cancer	4.42e-05	5.94e-05	CcSEcCtD
Varenicline—CHRNA7—Neuronal System—HRAS—hematologic cancer	4.41e-05	0.000651	CbGpPWpGaD
Varenicline—Hypertension—Epirubicin—hematologic cancer	4.41e-05	5.93e-05	CcSEcCtD
Varenicline—Feeling abnormal—Prednisone—hematologic cancer	4.39e-05	5.9e-05	CcSEcCtD
Varenicline—Asthenia—Dexamethasone—hematologic cancer	4.39e-05	5.9e-05	CcSEcCtD
Varenicline—Asthenia—Betamethasone—hematologic cancer	4.39e-05	5.9e-05	CcSEcCtD
Varenicline—Ill-defined disorder—Doxorubicin—hematologic cancer	4.39e-05	5.89e-05	CcSEcCtD
Varenicline—Nervous system disorder—Methotrexate—hematologic cancer	4.37e-05	5.87e-05	CcSEcCtD
Varenicline—Anaemia—Doxorubicin—hematologic cancer	4.37e-05	5.87e-05	CcSEcCtD
Varenicline—Thrombocytopenia—Methotrexate—hematologic cancer	4.36e-05	5.86e-05	CcSEcCtD
Varenicline—Gastrointestinal pain—Prednisone—hematologic cancer	4.36e-05	5.86e-05	CcSEcCtD
Varenicline—Nausea—Prednisolone—hematologic cancer	4.36e-05	5.86e-05	CcSEcCtD
Varenicline—Arthralgia—Epirubicin—hematologic cancer	4.35e-05	5.84e-05	CcSEcCtD
Varenicline—Chest pain—Epirubicin—hematologic cancer	4.35e-05	5.84e-05	CcSEcCtD
Varenicline—Myalgia—Epirubicin—hematologic cancer	4.35e-05	5.84e-05	CcSEcCtD
Varenicline—Agitation—Doxorubicin—hematologic cancer	4.34e-05	5.84e-05	CcSEcCtD
Varenicline—Anxiety—Epirubicin—hematologic cancer	4.34e-05	5.82e-05	CcSEcCtD
Varenicline—Pruritus—Dexamethasone—hematologic cancer	4.33e-05	5.82e-05	CcSEcCtD
Varenicline—Pruritus—Betamethasone—hematologic cancer	4.33e-05	5.82e-05	CcSEcCtD
Varenicline—Skin disorder—Methotrexate—hematologic cancer	4.33e-05	5.82e-05	CcSEcCtD
Varenicline—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	4.32e-05	5.8e-05	CcSEcCtD
Varenicline—Hyperhidrosis—Methotrexate—hematologic cancer	4.31e-05	5.79e-05	CcSEcCtD
Varenicline—Discomfort—Epirubicin—hematologic cancer	4.3e-05	5.77e-05	CcSEcCtD
Varenicline—Vomiting—Triamcinolone—hematologic cancer	4.29e-05	5.76e-05	CcSEcCtD
Varenicline—Malaise—Doxorubicin—hematologic cancer	4.26e-05	5.73e-05	CcSEcCtD
Varenicline—Rash—Triamcinolone—hematologic cancer	4.25e-05	5.72e-05	CcSEcCtD
Varenicline—Dry mouth—Epirubicin—hematologic cancer	4.25e-05	5.72e-05	CcSEcCtD
Varenicline—Dermatitis—Triamcinolone—hematologic cancer	4.25e-05	5.71e-05	CcSEcCtD
Varenicline—Vertigo—Doxorubicin—hematologic cancer	4.25e-05	5.71e-05	CcSEcCtD
Varenicline—Anorexia—Methotrexate—hematologic cancer	4.25e-05	5.71e-05	CcSEcCtD
Varenicline—Syncope—Doxorubicin—hematologic cancer	4.24e-05	5.7e-05	CcSEcCtD
Varenicline—Urticaria—Prednisone—hematologic cancer	4.24e-05	5.69e-05	CcSEcCtD
Varenicline—Headache—Triamcinolone—hematologic cancer	4.23e-05	5.68e-05	CcSEcCtD
Varenicline—Abdominal pain—Prednisone—hematologic cancer	4.22e-05	5.66e-05	CcSEcCtD
Varenicline—Body temperature increased—Prednisone—hematologic cancer	4.22e-05	5.66e-05	CcSEcCtD
Varenicline—Diarrhoea—Dexamethasone—hematologic cancer	4.19e-05	5.63e-05	CcSEcCtD
Varenicline—Diarrhoea—Betamethasone—hematologic cancer	4.19e-05	5.63e-05	CcSEcCtD
Varenicline—Palpitations—Doxorubicin—hematologic cancer	4.18e-05	5.61e-05	CcSEcCtD
Varenicline—Oedema—Epirubicin—hematologic cancer	4.17e-05	5.6e-05	CcSEcCtD
Varenicline—Hypotension—Methotrexate—hematologic cancer	4.16e-05	5.59e-05	CcSEcCtD
Varenicline—Loss of consciousness—Doxorubicin—hematologic cancer	4.16e-05	5.58e-05	CcSEcCtD
Varenicline—Infection—Epirubicin—hematologic cancer	4.14e-05	5.57e-05	CcSEcCtD
Varenicline—Cough—Doxorubicin—hematologic cancer	4.13e-05	5.54e-05	CcSEcCtD
Varenicline—Shock—Epirubicin—hematologic cancer	4.1e-05	5.51e-05	CcSEcCtD
Varenicline—Convulsion—Doxorubicin—hematologic cancer	4.1e-05	5.5e-05	CcSEcCtD
Varenicline—Nervous system disorder—Epirubicin—hematologic cancer	4.09e-05	5.49e-05	CcSEcCtD
Varenicline—Thrombocytopenia—Epirubicin—hematologic cancer	4.08e-05	5.49e-05	CcSEcCtD
Varenicline—Hypertension—Doxorubicin—hematologic cancer	4.08e-05	5.48e-05	CcSEcCtD
Varenicline—Tachycardia—Epirubicin—hematologic cancer	4.07e-05	5.47e-05	CcSEcCtD
Varenicline—Musculoskeletal discomfort—Methotrexate—hematologic cancer	4.06e-05	5.45e-05	CcSEcCtD
Varenicline—Skin disorder—Epirubicin—hematologic cancer	4.05e-05	5.44e-05	CcSEcCtD
Varenicline—Dizziness—Dexamethasone—hematologic cancer	4.05e-05	5.44e-05	CcSEcCtD
Varenicline—Dizziness—Betamethasone—hematologic cancer	4.05e-05	5.44e-05	CcSEcCtD
Varenicline—Hyperhidrosis—Epirubicin—hematologic cancer	4.03e-05	5.42e-05	CcSEcCtD
Varenicline—Insomnia—Methotrexate—hematologic cancer	4.03e-05	5.41e-05	CcSEcCtD
Varenicline—Myalgia—Doxorubicin—hematologic cancer	4.03e-05	5.41e-05	CcSEcCtD
Varenicline—Chest pain—Doxorubicin—hematologic cancer	4.03e-05	5.41e-05	CcSEcCtD
Varenicline—Arthralgia—Doxorubicin—hematologic cancer	4.03e-05	5.41e-05	CcSEcCtD
Varenicline—Anxiety—Doxorubicin—hematologic cancer	4.01e-05	5.39e-05	CcSEcCtD
Varenicline—Nausea—Triamcinolone—hematologic cancer	4.01e-05	5.38e-05	CcSEcCtD
Varenicline—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	4e-05	5.37e-05	CcSEcCtD
Varenicline—Discomfort—Doxorubicin—hematologic cancer	3.98e-05	5.34e-05	CcSEcCtD
Varenicline—Anorexia—Epirubicin—hematologic cancer	3.98e-05	5.34e-05	CcSEcCtD
Varenicline—Dyspnoea—Methotrexate—hematologic cancer	3.97e-05	5.34e-05	CcSEcCtD
Varenicline—Somnolence—Methotrexate—hematologic cancer	3.96e-05	5.32e-05	CcSEcCtD
Varenicline—Dry mouth—Doxorubicin—hematologic cancer	3.94e-05	5.29e-05	CcSEcCtD
Varenicline—Hypersensitivity—Prednisone—hematologic cancer	3.93e-05	5.28e-05	CcSEcCtD
Varenicline—Dyspepsia—Methotrexate—hematologic cancer	3.92e-05	5.27e-05	CcSEcCtD
Varenicline—Hypotension—Epirubicin—hematologic cancer	3.9e-05	5.24e-05	CcSEcCtD
Varenicline—Vomiting—Dexamethasone—hematologic cancer	3.89e-05	5.23e-05	CcSEcCtD
Varenicline—Vomiting—Betamethasone—hematologic cancer	3.89e-05	5.23e-05	CcSEcCtD
Varenicline—Decreased appetite—Methotrexate—hematologic cancer	3.87e-05	5.2e-05	CcSEcCtD
Varenicline—Rash—Dexamethasone—hematologic cancer	3.86e-05	5.19e-05	CcSEcCtD
Varenicline—Rash—Betamethasone—hematologic cancer	3.86e-05	5.19e-05	CcSEcCtD
Varenicline—Oedema—Doxorubicin—hematologic cancer	3.86e-05	5.18e-05	CcSEcCtD
Varenicline—Dermatitis—Dexamethasone—hematologic cancer	3.86e-05	5.18e-05	CcSEcCtD
Varenicline—Dermatitis—Betamethasone—hematologic cancer	3.86e-05	5.18e-05	CcSEcCtD
Varenicline—Gastrointestinal disorder—Methotrexate—hematologic cancer	3.85e-05	5.17e-05	CcSEcCtD
Varenicline—Fatigue—Methotrexate—hematologic cancer	3.84e-05	5.16e-05	CcSEcCtD
Varenicline—Headache—Dexamethasone—hematologic cancer	3.84e-05	5.15e-05	CcSEcCtD
Varenicline—Headache—Betamethasone—hematologic cancer	3.84e-05	5.15e-05	CcSEcCtD
Varenicline—Infection—Doxorubicin—hematologic cancer	3.83e-05	5.15e-05	CcSEcCtD
Varenicline—Asthenia—Prednisone—hematologic cancer	3.83e-05	5.14e-05	CcSEcCtD
Varenicline—Pain—Methotrexate—hematologic cancer	3.81e-05	5.12e-05	CcSEcCtD
Varenicline—Musculoskeletal discomfort—Epirubicin—hematologic cancer	3.8e-05	5.1e-05	CcSEcCtD
Varenicline—Shock—Doxorubicin—hematologic cancer	3.8e-05	5.1e-05	CcSEcCtD
Varenicline—Nervous system disorder—Doxorubicin—hematologic cancer	3.78e-05	5.08e-05	CcSEcCtD
Varenicline—Thrombocytopenia—Doxorubicin—hematologic cancer	3.78e-05	5.08e-05	CcSEcCtD
Varenicline—Pruritus—Prednisone—hematologic cancer	3.77e-05	5.07e-05	CcSEcCtD
Varenicline—Insomnia—Epirubicin—hematologic cancer	3.77e-05	5.07e-05	CcSEcCtD
Varenicline—Tachycardia—Doxorubicin—hematologic cancer	3.77e-05	5.06e-05	CcSEcCtD
Varenicline—Skin disorder—Doxorubicin—hematologic cancer	3.75e-05	5.04e-05	CcSEcCtD
Varenicline—Hyperhidrosis—Doxorubicin—hematologic cancer	3.73e-05	5.01e-05	CcSEcCtD
Varenicline—Dyspnoea—Epirubicin—hematologic cancer	3.72e-05	4.99e-05	CcSEcCtD
Varenicline—Somnolence—Epirubicin—hematologic cancer	3.71e-05	4.98e-05	CcSEcCtD
Varenicline—Anorexia—Doxorubicin—hematologic cancer	3.68e-05	4.94e-05	CcSEcCtD
Varenicline—Feeling abnormal—Methotrexate—hematologic cancer	3.67e-05	4.93e-05	CcSEcCtD
Varenicline—Dyspepsia—Epirubicin—hematologic cancer	3.67e-05	4.93e-05	CcSEcCtD
Varenicline—Diarrhoea—Prednisone—hematologic cancer	3.65e-05	4.9e-05	CcSEcCtD
Varenicline—Gastrointestinal pain—Methotrexate—hematologic cancer	3.64e-05	4.9e-05	CcSEcCtD
Varenicline—Nausea—Betamethasone—hematologic cancer	3.64e-05	4.89e-05	CcSEcCtD
Varenicline—Nausea—Dexamethasone—hematologic cancer	3.64e-05	4.89e-05	CcSEcCtD
Varenicline—Decreased appetite—Epirubicin—hematologic cancer	3.63e-05	4.87e-05	CcSEcCtD
Varenicline—Hypotension—Doxorubicin—hematologic cancer	3.61e-05	4.84e-05	CcSEcCtD
Varenicline—Gastrointestinal disorder—Epirubicin—hematologic cancer	3.6e-05	4.84e-05	CcSEcCtD
Varenicline—CHRNA4—Neuronal System—HRAS—hematologic cancer	3.6e-05	0.000531	CbGpPWpGaD
Varenicline—Fatigue—Epirubicin—hematologic cancer	3.6e-05	4.83e-05	CcSEcCtD
Varenicline—Pain—Epirubicin—hematologic cancer	3.57e-05	4.79e-05	CcSEcCtD
Varenicline—Constipation—Epirubicin—hematologic cancer	3.57e-05	4.79e-05	CcSEcCtD
Varenicline—Urticaria—Methotrexate—hematologic cancer	3.54e-05	4.76e-05	CcSEcCtD
Varenicline—Dizziness—Prednisone—hematologic cancer	3.53e-05	4.74e-05	CcSEcCtD
Varenicline—Body temperature increased—Methotrexate—hematologic cancer	3.52e-05	4.73e-05	CcSEcCtD
Varenicline—Abdominal pain—Methotrexate—hematologic cancer	3.52e-05	4.73e-05	CcSEcCtD
Varenicline—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	3.52e-05	4.72e-05	CcSEcCtD
Varenicline—Insomnia—Doxorubicin—hematologic cancer	3.49e-05	4.69e-05	CcSEcCtD
Varenicline—Dyspnoea—Doxorubicin—hematologic cancer	3.44e-05	4.62e-05	CcSEcCtD
Varenicline—Feeling abnormal—Epirubicin—hematologic cancer	3.44e-05	4.62e-05	CcSEcCtD
Varenicline—Somnolence—Doxorubicin—hematologic cancer	3.43e-05	4.61e-05	CcSEcCtD
Varenicline—Gastrointestinal pain—Epirubicin—hematologic cancer	3.41e-05	4.58e-05	CcSEcCtD
Varenicline—Dyspepsia—Doxorubicin—hematologic cancer	3.4e-05	4.56e-05	CcSEcCtD
Varenicline—Vomiting—Prednisone—hematologic cancer	3.39e-05	4.55e-05	CcSEcCtD
Varenicline—Rash—Prednisone—hematologic cancer	3.36e-05	4.52e-05	CcSEcCtD
Varenicline—Dermatitis—Prednisone—hematologic cancer	3.36e-05	4.51e-05	CcSEcCtD
Varenicline—Decreased appetite—Doxorubicin—hematologic cancer	3.35e-05	4.51e-05	CcSEcCtD
Varenicline—Headache—Prednisone—hematologic cancer	3.34e-05	4.49e-05	CcSEcCtD
Varenicline—Gastrointestinal disorder—Doxorubicin—hematologic cancer	3.33e-05	4.48e-05	CcSEcCtD
Varenicline—Fatigue—Doxorubicin—hematologic cancer	3.33e-05	4.47e-05	CcSEcCtD
Varenicline—Urticaria—Epirubicin—hematologic cancer	3.31e-05	4.45e-05	CcSEcCtD
Varenicline—Pain—Doxorubicin—hematologic cancer	3.3e-05	4.43e-05	CcSEcCtD
Varenicline—Constipation—Doxorubicin—hematologic cancer	3.3e-05	4.43e-05	CcSEcCtD
Varenicline—Abdominal pain—Epirubicin—hematologic cancer	3.3e-05	4.43e-05	CcSEcCtD
Varenicline—Body temperature increased—Epirubicin—hematologic cancer	3.3e-05	4.43e-05	CcSEcCtD
Varenicline—Hypersensitivity—Methotrexate—hematologic cancer	3.28e-05	4.41e-05	CcSEcCtD
Varenicline—Asthenia—Methotrexate—hematologic cancer	3.2e-05	4.3e-05	CcSEcCtD
Varenicline—Feeling abnormal—Doxorubicin—hematologic cancer	3.18e-05	4.27e-05	CcSEcCtD
Varenicline—Nausea—Prednisone—hematologic cancer	3.17e-05	4.26e-05	CcSEcCtD
Varenicline—Gastrointestinal pain—Doxorubicin—hematologic cancer	3.16e-05	4.24e-05	CcSEcCtD
Varenicline—Pruritus—Methotrexate—hematologic cancer	3.15e-05	4.24e-05	CcSEcCtD
Varenicline—Hypersensitivity—Epirubicin—hematologic cancer	3.07e-05	4.13e-05	CcSEcCtD
Varenicline—Urticaria—Doxorubicin—hematologic cancer	3.07e-05	4.12e-05	CcSEcCtD
Varenicline—Body temperature increased—Doxorubicin—hematologic cancer	3.05e-05	4.1e-05	CcSEcCtD
Varenicline—Abdominal pain—Doxorubicin—hematologic cancer	3.05e-05	4.1e-05	CcSEcCtD
Varenicline—Diarrhoea—Methotrexate—hematologic cancer	3.05e-05	4.1e-05	CcSEcCtD
Varenicline—Asthenia—Epirubicin—hematologic cancer	2.99e-05	4.02e-05	CcSEcCtD
Varenicline—Pruritus—Epirubicin—hematologic cancer	2.95e-05	3.96e-05	CcSEcCtD
Varenicline—Dizziness—Methotrexate—hematologic cancer	2.95e-05	3.96e-05	CcSEcCtD
Varenicline—Diarrhoea—Epirubicin—hematologic cancer	2.85e-05	3.83e-05	CcSEcCtD
Varenicline—Hypersensitivity—Doxorubicin—hematologic cancer	2.84e-05	3.82e-05	CcSEcCtD
Varenicline—Vomiting—Methotrexate—hematologic cancer	2.83e-05	3.81e-05	CcSEcCtD
Varenicline—Rash—Methotrexate—hematologic cancer	2.81e-05	3.77e-05	CcSEcCtD
Varenicline—Dermatitis—Methotrexate—hematologic cancer	2.81e-05	3.77e-05	CcSEcCtD
Varenicline—Headache—Methotrexate—hematologic cancer	2.79e-05	3.75e-05	CcSEcCtD
Varenicline—Asthenia—Doxorubicin—hematologic cancer	2.77e-05	3.72e-05	CcSEcCtD
Varenicline—Dizziness—Epirubicin—hematologic cancer	2.76e-05	3.7e-05	CcSEcCtD
Varenicline—Pruritus—Doxorubicin—hematologic cancer	2.73e-05	3.67e-05	CcSEcCtD
Varenicline—Vomiting—Epirubicin—hematologic cancer	2.65e-05	3.56e-05	CcSEcCtD
Varenicline—Nausea—Methotrexate—hematologic cancer	2.65e-05	3.56e-05	CcSEcCtD
Varenicline—Diarrhoea—Doxorubicin—hematologic cancer	2.64e-05	3.55e-05	CcSEcCtD
Varenicline—Rash—Epirubicin—hematologic cancer	2.63e-05	3.53e-05	CcSEcCtD
Varenicline—Dermatitis—Epirubicin—hematologic cancer	2.63e-05	3.53e-05	CcSEcCtD
Varenicline—Headache—Epirubicin—hematologic cancer	2.61e-05	3.51e-05	CcSEcCtD
Varenicline—Dizziness—Doxorubicin—hematologic cancer	2.55e-05	3.43e-05	CcSEcCtD
Varenicline—Nausea—Epirubicin—hematologic cancer	2.48e-05	3.33e-05	CcSEcCtD
Varenicline—Vomiting—Doxorubicin—hematologic cancer	2.45e-05	3.3e-05	CcSEcCtD
Varenicline—Rash—Doxorubicin—hematologic cancer	2.43e-05	3.27e-05	CcSEcCtD
Varenicline—Dermatitis—Doxorubicin—hematologic cancer	2.43e-05	3.27e-05	CcSEcCtD
Varenicline—Headache—Doxorubicin—hematologic cancer	2.42e-05	3.25e-05	CcSEcCtD
Varenicline—Nausea—Doxorubicin—hematologic cancer	2.29e-05	3.08e-05	CcSEcCtD
